title: FoxO proteins: regulation and molecular targets in liver cancer.
abstract: Human forkhead box class O (FoxO) transcription factors, activated in response to a wide range of external stimuli, like growth factors, insulin, nutrient levels and oxidative stress, are able to control several specific geneexpression programs. Besides their clear implication in metabolic processes, they appear to play a relevant role in tumour suppression by upregulation of genes involved in cell cycle arrest or apoptosis. Recent research efforts provide new insights into the molecular modulation of FoxO in liver cancer and disclose potential opportunities for developing new antitumor drugs. Through an intricate regulatory model, achieved via several post-translational modifications, including phosphorylation, acetylation, and ubiquitination, which control their subcellular localization and DNA binding activity, FoxO factors act as tumour suppressors. Low levels of FoxOs are associated with poor prognosis in cancer patients, and seem to confer chemotherapy resistance. Within FoxO members, FoxO3a appears to present anti-tumour properties in hepatocellular carcinoma, inducing the expression of pro-apoptotic genes, or interfering with signaling cascades commonly altered in this disease such as Wnt/β-catenin, PI3K/AKT/mTOR or MAPKs pathways. Here, we describe the main mechanisms of FoxO proteins regulation, and their cross-link with altered pathways in liver cancer. Moreover, based on the current knowledge of FoxO modulation, emphasis is placed on the development of novel agents which specifically activate FoxO family members and could be useful in the treatment of hepatocarcinoma.
authors.forename: S
authors.initials: S
authors.lastname: Carbajo-Pescador
authors.forename: J L
authors.initials: JL
authors.lastname: Mauriz
authors.forename: A
authors.initials: A
authors.lastname: García-Palomo
authors.affiliation: Institute of Biomedicine (IBIOMED), Campus Universitario, 24071, Leon, Spain. jgonga@unileon.es.
authors.forename: J
authors.initials: J
authors.lastname: González-Gallego
mesh_terms: D000107:Acetylation; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051858:Forkhead Transcription Factors / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D058990:Molecular Targeted Therapy; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D054875:Ubiquitination
chemical_list: D000970:Antineoplastic Agents; D051858:Forkhead Transcription Factors; D025521:Tumor Suppressor Proteins; D020928:Mitogen-Activated Protein Kinases